{
    "2020-12-09": [
        [
            {
                "time": "",
                "original_text": "医药生物2021年投资策略报告：不畏浮云遮望眼",
                "features": {
                    "keywords": [
                        "医药生物",
                        "投资策略",
                        "2021年"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2020-11",
                "original_text": "医药生物2020年1-11月血制品批签发：11月人白，静丙等出现明显下滑",
                "features": {
                    "keywords": [
                        "医药生物",
                        "血制品",
                        "批签发",
                        "人白",
                        "静丙",
                        "下滑"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}